Intellia Q1 2026: Lonvo-z Rolling BLA Advances Toward H1 2027 Launch; Nex-z Phase 3 MAGNITUDE Trials Resume After FDA Hold Lifted

Intellia Therapeutics announced Q1 2026 financial results and clinical pipeline updates on May 11, 2026. Lonvo-z (lonvoguran ziclumeran; in vivo CRISPR liver therapy for hereditary angioedema, HAE): Rolling BLA submission to the FDA is underway following the landmark Phase 3 HAELO trial results announced April 27, 2026 (87% attack reduction vs. placebo; 62% of patients entirely attack-free and therapy-free at six months vs. 11% placebo). All treatment-emergent adverse events were mild or moderate (Grade 1-2); no serious adverse events. Intellia targets U.S. commercial launch in H1 2027. Nex-z (nexiguran ziclumeran; in vivo CRISPR liver therapy for ATTR amyloidosis): The FDA had lifted clinical holds on both MAGNITUDE (ATTR-CM, cardiomyopathy) and MAGNITUDE-2 (ATTRv-PN, polyneuropathy) Phase 3 trials earlier in Q1 2026. As of the May 11 update, patient screening has resumed in both trials. Financial highlights: Q1 2026 collaboration revenue of $15.0M, beating analyst consensus of $13.81M (prior year Q1: comparable lower base). Net loss $96.2M ($0.81/share), improved from $114.3M in Q1 2025. Cash, cash equivalents, and marketable securities of $517.2M at March 31, 2026; plus approximately $207M gross from the April 2026 underwritten equity offering, funding operations into 2028 and well beyond the anticipated lonvo-z commercial launch. Intellia also plans to present at the Bank of America Securities Health Care Conference in Las Vegas on May 12, 2026.